It’s the end of the world as we know it; panic and mass hysteria. That is roughly the tone of recent coverage of the pharmacy changes arriving in 2027, and it is worth turning the volume down, because the truth is more complicated and considerably more useful.
Three federal changes land on the same prescription claims Jan. 1, 2027. Fifteen more Part D drugs take negotiated Medicare prices, the 340B rebate pilot goes live, and the CY 2027 Part D benefit redesign applies. None of them is a margin problem. All of them are timing problems, and timing problems do not show up where hospital finance teams are looking.
Start with a contradiction already on the record. In April, CMS reported that maximum fair price refunds are reaching dispensing entities within 21 days of date of service, on average. In February, the National Community Pharmacists Association told the CMS Administrator that in a survey of more than 500 pharmacy owners and managers, 67% were waiting more than 22 days and 22% were waiting beyond 28.
Both are true. Manufacturer performance varies widely, and entities that have not elected electronic funds transfer get paper checks and wait longer. An average across counterparties hides counterparty variance, and counterparty variance is what a treasury function has to plan around.
Why the exposure is uneven
Fitch Ratings’ 2026 medians put days cash on hand at 212 across 222 rated nonprofit organizations. Chartis puts rural and community hospitals at 29. Debt covenants commonly sit between, requiring 40 to 80 days cash on hand. The identical policy change is a rounding error at one end of that distribution and an event of default at the other.
Scale cuts the same way. The Health Resources and Services Administration puts the pilot drugs at roughly 5.5% of total 340B sales, and critical access hospitals purchased $1.5 billion in 340B drugs nationally in 2025, so the whole cohort’s pilot-drug volume is near $80 million across more than a thousand facilities. For a median facility the exposure is small. But high-cost drugs bought through specialty channels were 38.1% of 340B units and 61.9% of 340B dollars. The money clusters, which is what makes a national average useless as a planning input.
Four steps to your own number
First, isolate the affected volume by NDC across all payers and indications, not Medicare alone. Maximum fair price effectuation reaches only Part D until 2028; the rebate pilot reaches commercial, Medicaid, and clinician-administered volume from day one. Any estimate scoped to Medicare understates hospital exposure.
Second, build the timing profile. This is where the exercise stops being arithmetic and becomes something closer to orchestration. Leonard Bernstein, writing in The Joy of Music, described the conductor as “a kind of sculptor whose element is time instead of marble.” A covered entity in 2027 is reading from a score with four independent parts, and the entrances do not line up on their own.
You purchase at wholesale acquisition cost. The plan pays a clean electronic Part D claim within 14 days. The manufacturer has up to 14 days after receiving claim data, plus up to five business days of banking transfer. Separately, you have 45 calendar days from dispense to submit the 340B rebate claim, and the manufacturer has 10 calendar days to pay or deny, with the clock restarting if your submission comes back incomplete. Set all of that against your own wholesaler payment terms, because that single clause determines whether a float exists at your organization at all.
Third, net it. The rebate equals wholesale acquisition cost less the 340B ceiling price, regardless of what you actually paid, so an entity acquiring below list nets more than the ceiling on every unit. Against that, subtract any sub-ceiling pricing you lose and the prompt-pay discount you forfeit if payment timing shifts. Apply your line rate to the remainder.
Fourth, convert the result to days cash on hand and test it against your covenant floor rather than a national median.
Two places the exposure doubles
Read your state Medicaid program’s instruction. At least two states, including Massachusetts and Colorado, have published claim processing instructions telling pharmacies not to bill the pre-rebate purchase price for pilot drugs and requiring the submitted ingredient cost to be no more than the 340B ceiling price. Work that through. You pay wholesale acquisition cost at purchase, you bill Medicaid at the ceiling price at dispense, and then you wait for a rebate that arrives no sooner than 10 days after you submit the claim, and as late as 55 days after dispense if you use the full submission window. Both halves of the transaction move to their worst position on day zero and only one is restored, which makes submission speed a treasury decision rather than a clerical one.
And for cost-reimbursed facilities, the margin is not where the modeling assumes. Medicare pays critical access hospitals 101 percent of reasonable cost for outpatient facility services, drugs included, so the 340B margin sits in commercial and pharmacy dispensing, which is exactly what the all-payer pilot reaches. Meanwhile roughly 30 states prohibit payers from reimbursing 340B claims at lower rates, holding the revenue side steady while the cost side moves.
What to do before January
Pull the wholesaler agreement and read the payment terms and prompt-pay discount. Confirm pricing-system access for whoever will verify rebate amounts. Identify unreplenished inventory by NDC so you can use the 15-day transition grace period. Confirm Medicaid carve-in status before the mid-December quarterly snapshot. Elect electronic funds transfer rather than paper check.
Two accommodation pathways exist and almost nobody is using them. On the Medicare side, dispensing entities may self-identify as anticipating material cash flow concerns during data module enrollment, and manufacturers must include a mitigation process in their effectuation plans. On the 340B side, manufacturer plans must describe any exception that would not apply broadly, with lack of third-party administrator access and rural status given as the agency’s own examples. That exception has to be requested.
Then measure from the first claim. HRSA published its own trigger. If covered entities report a manufacturer consistently exceeding the 10-day window, the agency states it could review a sample and, finding five or more percent delayed without justification, begin removal proceedings. The same threshold applies to unjustified denials. Tracking your payment and denial rates against five percent from Jan. 1 is not complaining. It is building the record the agency said it would act on.
The part that makes this a finance problem
Under vendor consideration guidance, a 340B rebate is not revenue. It reduces the carrying value of inventory while units are held and cost of sales as they dispense. It is a vendor receivable, so it never ages in patient accounting and never enters net days in accounts receivable. Denied rebates true up through cost of sales, so they miss every denial metric a revenue cycle team tracks. The only footprints are a higher inventory balance and a lower cash balance, and neither one names the cause.
An organization can run an entire quarter of deteriorating working capital from this program with every indicator on its revenue cycle scorecard green. That is not a failure of the scorecard. It is a category the scorecard was never built to hold, and the only way to see it is to go looking on purpose.
We have done this before. The 2024 direct and indirect remuneration transition was net favorable in the long run and still produced a multi-quarter liquidity event, because nobody modeled the transition. Same failure mode, more counterparties, and this time the arithmetic is available in advance. It may well be the end of the world as we know it; whether anyone feels fine on Jan. 2 depends on what gets calculated first.
Dr. Mildenberger is specialty pharmacy manager and compliance officer at Sidney (Neb.) Regional Medical Center, a critical access hospital that participates in the 340B Drug Pricing Program. The views expressed are his own.
